Anika Therapeutics | ANIK - Ebit

Stock Price
14.40
Daily Change
0.04 0.28%
Monthly
39.81%
Yearly
-15.44%
Q1 Forecast
13.92

Anika Therapeutics reported $-4.28M in EBIT for its fiscal quarter ending in March of 2025.





Ebit Change Date
Abbott USD 2.54B 358M Dec/2025
Agenus USD -13.31M 19.08M Mar/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Anika Therapeutics USD -4.28M 3.58M Mar/2025
Arrowhead Research USD 40.81M 17.01M Dec/2025
Enanta Pharmaceuticals USD -23.54M 6.31M Dec/2024
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Heron Therapeutics USD -4.46M 5.76M Sep/2024
Insmed USD -249.71M 11.64M Dec/2025
Integra LifeSciences USD 66M 54.24M Dec/2025
Intrexon USD -26.3M 2.91M Jun/2024
J&J USD 5.11B 2.3B Dec/2025
Karyopharm Therapeutics USD -26.28M 1.84M Sep/2024
Ligand Pharmaceuticals USD 158.89M 115.32M Sep/2025
MacroGenics USD 20.16M 55.51M Sep/2025
Merit Medical Systems USD 54.2M 11.58M Dec/2025
Rigel Pharmaceuticals USD 447K 1.52M Jun/2024
Sanofi EUR 1.7B 2.17B Dec/2025
Smith & Nephew USD 440M 50M Dec/2025
Stryker USD 1.97B 609M Dec/2025
Surmodics USD -322K 2.13M Dec/2023
Veracyte USD 24.63M 1.52M Dec/2025
Xencor USD -53.63M 6.11M Dec/2025
Zimmer Biomet Holdings USD 302.9M 35.4M Dec/2025